Physician profile
Mark Finch
NPI 1336116995
$28,006.07
in general payments reported to CMS, 2019-2025
30 companies · $4,587 in 2025
The $4,587 reported for 2025 was more than what 90% of Nuclear Cardiology providers received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,465 · 2020: $1,285 · 2021: $646 · 2022: $7,568 · 2023: $9,499 · 2024: $1,955 · 2025: $4,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,000 · Food and Beverage: $5,894 · Travel and Lodging: $2,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,000.00 |
| Food and Beverage | $5,893.93 |
| Travel and Lodging | $2,148.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $16,541.92 | 2019-2025 | Watchman Access System, Watchman Flx, Watchman |
| Heartflow, INC. | $4,890.55 | 2022-2025 | Ffrct |
| Pfizer INC. | $1,170.88 | 2019-2025 | |
| Ge Healthcare | $1,110.92 | 2025 | |
| Amgen INC. | $895.21 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $776.08 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $320.23 | 2019-2023 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $291.60 | 2020-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $222.43 | 2019-2024 | |
| Edwards Lifesciences Corporation | $215.04 | 2023-2025 | Evoque, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.40 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $158.34 | 2019-2020 | |
| Amarin Pharma, INC. | $156.33 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $138.56 | 2024-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $131.02 | 2021-2024 | Verquvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $128.20 | 2025 | |
| Philips North America LLC | $119.75 | 2022-2024 | (5044) Mcot |
| Atricure, INC. | $105.04 | 2022 | |
| Esperion Therapeutics, INC. | $101.45 | 2020-2023 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $94.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $80.79 | 2019-2023 | Wainua, Farxiga |
| Kowa Pharmaceuticals America, INC. | $36.00 | 2019 | |
| Kestra Medical Technology Services, INC. | $34.76 | 2023-2024 | Assure Wcd |
| Medtronic, INC. | $30.91 | 2025 | Advisa Dr Mri Surescan |
| Avinger INC. | $23.72 | 2022 | |
| Scpharmaceuticals INC. | $20.39 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $16.38 | 2024 | Opsumit, Uptravi |
| Impulse Dynamics (USA) INC. | $12.23 | 2022 | |
| Gilead Sciences, INC. | $11.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Finch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.